ABO-Blood Group Associates With Survival Outcomes in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.

ABSTRACT:

Purpose

In patients with metastatic non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression, there is still a lack of biomarkers to identify patients with maximum benefit from first-line treatment with checkpoint inhibitor therapy (CIT) alone. This work examines the impact of different ABO blood groups (BG) on the response to CIT monotherapy.

Methods

Retrospective analysis of patients with stage IV NSCLC and high PD-L1 expression (tumor proportional score/TPS ≥ 50%), receiving first-line therapy with pembrolizumab alone or in combination with chemotherapy at the West German Cancer Center from 2017 to 2022. Study endpoints were overall survival (OS) and progression-free survival (PFS).

Results

Eighty-two patients were included in the a

SUBMITTER: Certa F 

PROVIDER: S-EPMC11925720 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature